Tag: Gensight
GenSight Biologics announces the drawing of the first tranche of its credit agreement with the EIB – 02/06/2023 at 18:29
(AOF) – GenSight Biologics announces the drawdown of 8 million euros under the first tranche of its credit agreement with the European Investment Bank. The biopharmaceutical company specializing in gene…
GenSight Biologics obtains 12 ME of financing through a convertible bond issue
(Boursier.com) — GenSight Biologicsa biopharmaceutical company dedicated to the development and commercialization of innovative gene therapies for neurodegenerative diseases of the retina and central nervous system, announced today that it…
GenSight: issue of OCA for the benefit of Heights Capital
(CercleFinance.com) – GenSight Biologics announces that it has signed a subscription agreement for an amount of 12 million euros in the form of a bond issue convertible into shares with…
Gene therapy: GenSight Biologics raises 12 million euros from an American fund – 12/23/2022 at 10:17
(AOF) – GenSight Biologics, a biopharmaceutical company dedicated to the development and commercialization of gene therapies for neurodegenerative diseases of the retina and central nervous system, announces that it has…
GenSight obtains a loan of 35 million euros from the European Investment Bank – 04/11/2022 at 09:57
(AOF) – GenSight Biologics (a biopharmaceutical company dedicated to the development and commercialization of innovative gene therapies for neurodegenerative diseases of the retina and disorders of the central nervous system)…
GenSight: EIB financing, the action takes off – 04/11/2022 at 11:44
(CercleFinance.com) – GenSight Biologics announced on Friday that it had obtained a loan of 35 million euros from the European Investment Bank, which allows the action of the biopharmaceutical company…
Gensight biologics: ‘Low-dilutive’ financing being finalized
Read also (CercleFinance.com) – GenSight Biologics reported on Friday evening a cash position of 13.9 million as of September 30, compared to 24.1 million euros as of June 30. In…
GenSight: ‘low dilution’ financing being finalized – 10/31/2022 at 11:43 am
(CercleFinance.com) – GenSight Biologics reported on Friday evening a cash position of 13.9 million as of September 30, compared to 24.1 million euros as of June 30. In a press…
Gensight starts the week on a high note
The biotech announces the successful production of the first pilot batch, integrating the improvements in the manufacturing process of Lumevoq. Gensight starts the week on a high note | Photo…
GenSight Biologics: produced pilot batch of LUMEVOQ – 09/19/2022 at 10:54 am
(CercleFinance.com) – GenSight Biologics announces the successful production of the first pilot batch incorporating improvements in the manufacturing process of LUMEVOQ, the gene therapy for Leber’s hereditary optic neuropathy (LHON)…
GenSight Biologics: produces the first pilot batch of LUMEVOQ – 09/19/2022 at 11:05 am
(CercleFinance.com) – GenSight Biologics announces the successful production of the first pilot batch incorporating improvements in the manufacturing process of LUMEVOQ, the gene therapy for Leber’s hereditary optic neuropathy (LHON)…
Gensight biologics: Recruiting for the launch of Lumevoq
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…